Telitacicept versus belimumab in proliferative lupus nephritis
In this preliminary study, telitacicept appears to induce earlier renal and immunologic remission than belimumab, along with a potential reduction in the need for glucocorticoids and immunosuppressants. Further validation in larger studies is needed.
Authors
- Ling-Xu Li
- biao Liu
- Man-Zhu Zhang
- Jia-Wei Shan
- Xiao-Ying Yun
- Bing Li
- Chang Wang
Institutions
- Harbin Medical University (CN)
- Hainan Center for Disease Control & Prevention (CN)
- Second Affiliated Hospital of Harbin Medical University (CN)
- First Affiliated Hospital of Harbin Medical University (CN)
- Hainan Medical University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-01-19
- DOI
- https://doi.org/10.3389/fimmu.2025.1715593
- Primary Topic
- Systemic Lupus Erythematosus Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China